Involvement of transforming growth factor alpha/epidermal growth factor receptor autocrine growth mechanism in an ovarian cancer cell line in vitro.
Although transforming growth factor (TGF) alpha and epidermal growth factor (EGF) receptor (EGFR) autocrine mechanism is widely demonstrated in many kinds of cancers, its biological significances still remain circumstantial. We critically assessed the significance of this mechanism on the growth of an ovarian cancer cell line. Northern blot analysis in polyadenylated RNA isolated from cells by using 32P-labeled pre-TGF alpha, EGRF, and prepro-EGF complementary DNAs as probes revealed that pre-TGF alpha and EGFR but not prepro-EGF gene transcripts were expressed in the cell. TGF alpha and EGFR but not EGF proteins were observed by immunocytochemical stainings, using monoclonal antibodies against human TGF alpha, EGFR, and EGF, respectively. This cell line possessed a class of high affinity EGF receptor by 125I-EGF binding studies; Kd being 2.9 x 10(-10) M and Bmax to be 7.7 x 10(4) sites/cell. As much as 1.12 +/- 0.14 ng (SD; n = 3)/10(7) cells/24 h of TGF alpha was secreted in the conditioned media. These results suggested the expression of a TGF alpha/EGFR autocrine mechanism in this cell line. We, therefore, assessed the biological significance of this mechanism on the growth of this cell line in serum-free monolayer cell cultures. Although 0.1, 1.0, and 10 nM concentrations of TGF alpha did not show significant growth promotion, monoclonal antibodies against TGF alpha and EGFR but not EGF significantly inhibited cell growth. All these data suggested the biological importance of a TGF alpha/EGFR autocrine mechanism on the growth of this cell line in vitro.
Morishige
K
K
Department of Obstetrics and Gynecology, Osaka University Medical School, Japan.
Kurachi
H
H
Amemiya
K
K
Adachi
H
H
Inoue
M
M
Miyake
A
A
Tanizawa
O
O
Sakoyama
Y
Y
D000911:Antibodies, Monoclonal; D015295:Antigens, Tumor-Associated, Carbohydrate / Q000032:analysis; D014408:Biomarkers, Tumor / Q000032:analysis; D015152:Blotting, Northern; D002455:Cell Division / Q000187:drug effects / Q000502:physiology*; D002460:Cell Line; D016895:Culture Media, Serum-Free; D003537:Cystadenoma; D004815:Epidermal Growth Factor / Q000235:genetics / Q000378:metabolism / Q000494:pharmacology; D066246:ErbB Receptors / Q000235:genetics / Q000502:physiology*; D005260:Female; D006801:Humans; D007700:Kinetics; D010051:Ovarian Neoplasms; D011061:Poly A / Q000235:genetics / Q000302:isolation & purification; D011498:Protein Precursors / Q000235:genetics; D012313:RNA / Q000235:genetics / Q000302:isolation & purification; D012333:RNA, Messenger; D016211:Transforming Growth Factor alpha / Q000235:genetics / Q000494:pharmacology / Q000502:physiology*; D016212:Transforming Growth Factor beta / Q000235:genetics
D000911:Antibodies, Monoclonal; D015295:Antigens, Tumor-Associated, Carbohydrate; D014408:Biomarkers, Tumor; D016895:Culture Media, Serum-Free; D011498:Protein Precursors; D012333:RNA, Messenger; D016211:Transforming Growth Factor alpha; D016212:Transforming Growth Factor beta; C042652:epidermal growth factor precursor; D011061:Poly A; D004815:Epidermal Growth Factor; D012313:RNA; D066246:ErbB Receptors